Perspective Therapeutics

CATX · NYSE American

$2.30+$0.11 (+5.02%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $2.19

Latest news

Press releaseOct 8, 6:16 AM ETGlobe Newswire
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
Press releaseOct 7, 6:16 AM ETGlobe Newswire
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
Press releaseOct 2, 11:46 AM ETGlobe Newswire
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
NewsSep 21, 5:01 AM ETAvi Kapoor
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
NewsSep 18, 1:52 PM ETVandana Singh
This $3 Biotech Could Be Worth $11.45, Analyst Says
Press releaseSep 14, 6:16 AM ETGlobe Newswire
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
Press releaseSep 11, 6:00 AM ETGlobe Newswire
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
Press releaseAug 10, 4:22 PM ETGlobe Newswire
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results
Press releaseJul 31, 6:30 AM ETGlobe Newswire
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
Press releaseJul 28, 6:30 AM ETGlobe Newswire
Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
Press releaseJul 17, 12:22 PM ETGlobe Newswire
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026
NewsJul 14, 8:03 AM ETAvi Kapoor
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Press releaseJul 8, 6:30 AM ETGlobe Newswire
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor
Press releaseJun 3, 6:30 AM ETGlobe Newswire
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
Press releaseMay 21, 5:51 PM ETGlobe Newswire
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
Press releaseMay 18, 6:30 AM ETGlobe Newswire
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
Press releaseMay 11, 4:07 PM ETGlobe Newswire
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
NewsMay 11, 7:11 AM ET
Earnings Scheduled For May 11, 2026
Press releaseApr 24, 6:30 AM ETGlobe Newswire
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
Press releaseApr 20, 6:00 AM ETGlobe Newswire
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
Press releaseApr 2, 7:00 AM ETGlobe Newswire
Perspective Therapeutics to Participate in Upcoming Investor Conferences
Press releaseMar 17, 4:45 PM ETGlobe Newswire
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
Press releaseMar 16, 4:07 PM ETGlobe Newswire
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
NewsMar 16, 7:11 AM ET
Earnings Scheduled For March 16, 2026
Press releaseFeb 17, 11:17 AM ETPRNewswire
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
Press releaseFeb 17, 7:00 AM ETGlobe Newswire
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
Press releaseJan 12, 7:00 AM ETGlobe Newswire
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
Press releaseJan 9, 7:00 AM ETGlobe Newswire
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
Press releaseDec 18, 7:00 AM ETGlobe Newswire
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Press releaseDec 4, 7:00 AM ETGlobe Newswire
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
NewsNov 10, 6:12 AM ET
Earnings Scheduled For November 10, 2025
NewsAug 13, 4:32 AM ET
Earnings Scheduled For August 13, 2025
NewsAug 12, 4:02 PM ET
A Look Ahead: Perspective Therapeutics's Earnings Forecast
NewsMay 12, 4:32 AM ET
Earnings Scheduled For May 12, 2025
NewsMar 26, 4:32 AM ET
Earnings Scheduled For March 26, 2025
NewsMar 13, 2:52 PM ETVandana Singh
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
NewsJan 24, 12:18 PM ETVandana Singh
Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars
NewsNov 21, 10:19 AM ETAvi Kapoor
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors

Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium

Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026

Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket

This $3 Biotech Could Be Worth $11.45, Analyst Says

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

Earnings Scheduled For May 11, 2026

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics to Participate in Upcoming Investor Conferences

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Earnings Scheduled For March 16, 2026

New Treatment Modalities Are Reaching Cancers That Resisted Everything Else

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

Earnings Scheduled For November 10, 2025

Earnings Scheduled For August 13, 2025

A Look Ahead: Perspective Therapeutics's Earnings Forecast

Earnings Scheduled For May 12, 2025

Earnings Scheduled For March 26, 2025

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars

Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings